The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.
D'Arena, G., Valentini, C., Pietrantuono, G., Guariglia, R., Martorelli, M., Mansueto, G. R., Villani, O., Onofrillo, D., Falcone, A., Specchia, G., Semenzato, G., Di Renzo, N., Mastrullo, L., Venditti, A., Ferrara, F., Palumbo, A., Pagano, L., Musto, P., Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party, <<ANNALS OF ONCOLOGY>>, 2012; 23 (6): 1499-1502. [doi:10.1093/annonc/mdr480] [http://hdl.handle.net/10807/3787]
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
Mansueto, Giovanna Rosaria;Venditti, Antonella;Ferrara, Ferdinando;Pagano, Livio;
2012
Abstract
The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
